-

03:37:05 PM

SRRK Stock News

SRRK - Scholar Rock Holding Corp

09/19/23 8:00 AM

Nasdaq : SRRK

clinical trial

Scholar Rock Announces Completion of Enrollment for the Phase 3 SAPPHIRE Trial

Efficacy and safety data at 36 months, and an analysis of patient-reported outcome measures such as fatigue, mobility, and activities of daily living, will be presented during two poster presentations at the 28 th Annual Congress of the World Muscle Society from October 3– 7 in Charleston, South Carolina, USA.. Title: Effect of apitegromab on PEDI-CAT and...

RHEA-AI

neutral

09/15/23 4:15 PM

Nasdaq : SRRK

management

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock, a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 8,750 shares of its common stock to one newly hired employee, consisting of inducement stock...

RHEA-AI

neutral

08/18/23 4:15 PM

Nasdaq : SRRK

management

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock, a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 150,938 shares of its common stock to 8 newly hired employees, consisting of inducement stock...

RHEA-AI

neutral

08/09/23 4:15 PM

Nasdaq : SRRK

earnings

Scholar Rock Reports Second Quarter 2023 Financial Results and Highlights Business Progress

Scholar Rock, a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results and corporate updates for the second quarter ended June 30, 2023.. “We continue to advance our apitegromab program, notably with the recent presentation of...

RHEA-AI

neutral

07/13/23 8:00 AM

Nasdaq : SRRK

management

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock, a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 72,625 shares of its common stock to 6 newly hired employees, consisting of inducement stock...

RHEA-AI

neutral

06/30/23 11:00 AM

Nasdaq : SRRK

clinical trial

New 36-Month Apitegromab Extension Data Reinforce Long-Term Substantial and Sustained Improvement of Motor Function in Phase 2 TOPAZ Trial Patients with Nonambulatory Spinal Muscular Atrophy

Scholar Rock, a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced new data from the Phase 2 TOPAZ trial extension period evaluating patient outcomes at 36 months of treatment with apitegromab. These data showed that continued treatment...

RHEA-AI

neutral

06/15/23 8:00 AM

Nasdaq : SRRK

management

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock, a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 216,563 shares of its common stock to 8 newly hired employees, consisting of inducement stock...

RHEA-AI

neutral

06/01/23 4:05 PM

Nasdaq : SRRK

conferences

Scholar Rock to Present at the Jefferies Healthcare Conference

Scholar Rock, a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the Jefferies Healthcare Conference on Thursday, June 8, 2023, at 3:00 p.m. ET. A live webcast of the presentation may be accessed by visiting...

RHEA-AI

neutral

05/10/23 8:00 AM

Nasdaq : SRRK

management

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock, a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the Company granted inducement equity awards covering an aggregate of 49,176 shares of its common stock to four newly hired employees, consisting of inducement stock...

RHEA-AI

neutral

05/09/23 7:30 AM

Nasdaq : SRRK

earnings

Scholar Rock Reports First Quarter 2023 Financial Results and Highlights Business Progress

Scholar Rock, a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results and corporate updates for the first quarter ended March 31, 2023.. Continued progress towards completion of enrollment for Phase 3 SAPPHIRE clinical...

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 Next

SRRK Data

IndustryResearch and Development in Biotechnology
Websitehttps://scholarrock.com/
Security nameScholar Rock Holding Corp
SectorProfessional, Scientific, and Technical Services
Tags
- Health Technology
- Biotechnology
CountryUS

About Scholar Rock Holding Corp

scholar rock® is a biotechnology company focused on discovering and developing a new class of biologic therapies called "niche modulators" that selectively target the activation of growth factors in the disease microenvironment. our initial proprietary and partnered drug discovery programs target specific growth factors, including members of the tgf-beta superfamily, which play a fundamental role in regulating cell growth and differentiation and are present in the microenvironments of significant diseases such as fibrosis, diseases of the musculoskeletal systems, and autoimmune diseases. the company’s therapeutic approach is enabled by discoveries made by scholar rock’s scientific founders—professors timothy springer, phd, and leonard zon, md, both of children's hospital boston and harvard medical school—related to the molecular mechanisms of growth factor activation. scholar rock is backed by leading life sciences investors, including polaris partners, arch venture partners, timothy s